Announcement • Jan 10

Sutro Biopharma, Inc. Announces Results from Phase 1 Dose-Expansion Study of STRO-002

Sutro Biopharma, Inc. announced results from a Phase 1 dose-expansion study of STRO-002 (luvelta), a novel Folate receptor alpha (FolRa)-targeting ADC and interim safety data from exploratory cohort C, a cohort of 15 patients with advanced ovarian cancer treated at the higher dose of luvelta, (5.2mg/kg), along with prophylactic pegfilgrastim. Additionally, the company provided details on the design of the registration-directed Phase 2/3 study, REFRaME, to start in the second quarter of 2023. Results demonstrated that luvelta provided substantial clinical benefit in FolRa-selected patients, defined by Tumor Proportion Score (TPS) of >25%, with a 37.5% overall response rate (ORR), median duration of response (median DOR) of 5.5 months, and median progression free survival (median PFS) of 6.1 months, regardless of starting dose. Results also demonstrated the higher starting dose of 5.2 mg/kg providing greater patient benefit compared to the lower dose of 4.3mg/kg. FolRa-selected patients account for approximately 80% of the patient population in advanced ovarian cancer, as represented in the patient stratification in the Phase 1 study. Consistent with prior luvelta data, the primary adverse event from the dose-expansion cohort was predominantly asymptomatic neutropenia, with no meaningful ocular toxicity signals or complications reported. In cohort C, an additional 15 patients with advanced ovarian cancer were enrolled and treated with prophylactic pegfilgrastim on Day 8 after each 5.2 mg/kg administration of luvelta. Initial data on neutropenia and dose delays were available on the first 10 patients, which showed that patients in cohort C experienced substantial decreases in neutropenia and potential increases in dose intensity, due to decreased dose delays. Summary of Results from Phase 1 Dose-Expansion Study: Based on the results, luvelta has demonstrated the potential to provide meaningful clinical benefit to a substantially broader patient population than the on-label patient population of the approved FolRa-targeting agent: Patients who were FolRa-selected, defined by TPS>25%, regardless of starting dose, demonstrated an ORR of 37.5% (n=32) with a median DOR of 5.5 months (n=12) and a median PFS of 6.1 months (n=35); Targeted luvelta patient population is approximately 80% of advanced ovarian cancer patients based on pooled Phase 1 biomarker data; Luvelta demonstrated a FolRa-dependent response, with patients who were unselected for FolRa (TPS=25%) demonstrating an 11.1% ORR (n=9) with a median DOR of 2.9 months (n=1) and a median PFS of 3.8 months (n=9). Luvelta, when given to patients at a starting dose of 5.2 mg/kg, provided greater patient benefit than a starting dose of 4.3 mg/kg: FolRa-selected patients given the higher dose of luvelta (5.2 mg/kg) demonstrated higher response rates: ORR of 43.8% (n=16); Median DOR of 5.4 months (n=7); Median PFS of 6.6 months (n=16); FolRa-selected patients given the lower dose of luvelta (4.3 mg/kg) demonstrated: ORR of 31.3% (n=16); Median DOR of 13 months (n=5); Median PFS of 6.1 months (n=19). Consistent with earlier reported data, the primary adverse event from the dose-expansion cohort was asymptomatic, transient neutropenia; Cohort C was initiated to explore the use of prophylactic pegfilgrastim for patients treated with the higher dose of luvelta (5.2mg/kg). Early results in the initial 10 patients in cohort C, when compared to patients who were not given prophylactic pegfilgrastim in the dose-expansion cohort at the higher dose (5.2mg/kg), showed substantial reductions in Grade 3+ neutropenia and in instances of dose delays: Grade 3+ neutropenia was reduced from 66.7% to 10.0%, resulting in an 85.0% decrease in Grade 3+ neutropenia rates at the first cycle of luvelta (p=0.006); Instances of dose delays at the second cycle of luvelta were reduced by 60.6% (p=0.021). Planned Phase 2/3 Study Details: As discussed with the U.S. Food and Drug Administration (FDA), the Phase 2/3 REFRaME study is planned to begin with a randomized, run-in dose confirmation phase. In this phase of the trial, 25 patients will be evaluated at the 5.2 mg/kg dose with pegfilgrastim delivered prophylactically for two cycles followed by a step-down dose to 4.3 mg/kg. The other 25 patients will be evaluated from the start at the 4.3 mg/kg dose without prophylactic pegfilgrastim. Following this 50-patient phase of the study, additional patients will be randomized between these two luvelta dose levels, and standard of care (chemotherapy). Upon agreement with FDA on the go-forward dose versus standard of care, the dose level of luvelta not chosen will be dropped. Upon having data on approximately 110 patients in the selected dose of luvelta arm, Sutro will look to apply for accelerated approval based on ORR as the primary endpoint. At the end of the Phase 3 portion of the trial, full approval can be sought based on PFS as the primary endpoint comparing the luvelta arm (n=160) and the standard of care arm (n=160).

Seeking Alpha • Aug 16

Sutro Biopharma: Partnership Progress Warrants Exposure

Shares of Sutro Biopharma have lost one-third of their value over the past 3 years. Consolidation in the antibody drug conjugate space has made it an attractive area for drug development. Sutro has inked a number of partnerships recently and management commentary leads me to believe that more are coming. Internal pipeline leaves much to be desired, but STRO-002 could have a path forward to a broad population if neutropenia is adequately addressed. I consider STRO a Buy below the $6 level. Key risks include competition in ovarian cancer and with FRα target, as well as discontinuation of partnerships or certain assets. Shares of Sutro Biopharma (STRO) have lost 68% since my December 2020 article extolled the advantages of its cell free ADC platform. At the time, I considered the stock to be a Buy after promising initial data for STRO-002 in ovarian cancer that seemed indicative of broad applicability. Over a 3-year timeframe, shares have lost one-third of their value as lead drug candidates move forward in the clinic and big pharma collaborations made significant progress. After a reader mentioned this name, I decided to revisit given my interest in the ADC space, differentiated technology and advancements particularly with partnered efforts. Another point influential in my revisiting was the phase 3 success of ADC peer ImmunoGen (IMGN), whose drug mirvetuximab is limited to FRα-high expressors whereas in the past I noted that Sutro’s STRO-002 appears to have a more broadly-applicable profile (though with significant tolerability challenges). Lastly, the China licensing deal made this name even more interesting given terms (respectable $40 million upfront cash payment) and specific language (plans now in the works to try the STRO-001 in indications of TNBC and NSCLC). This was followed by Astellas iADC pact including $90M upfront payment. Chart FinViz Figure 1: STRO weekly chart (Source: Finviz) When looking at charts, clarity often comes from taking a look at distinct time frames in order to determine important technical levels and get a feel for what's going on. In the weekly chart above, we can see shares rise to a high of $28 in early 2021 on heels of early data for STRO-002 in heavily pretreated ovarian cancer patients. From there, shares have fallen to a low in the mid- single digits and appear to have bottomed. My initial take is that the current valuation offers investors an attractive point of entry, but as I have less confidence in the internal pipeline and more in partnered efforts, I think this is a multi-year story that will require significant patience and long-term mindset. Overview Reflecting on my December 2020 article, here are our previously stated keys to the bullish thesis: Initially, Sutro’s lead solid tumor program targeting folate-receptor alpha (FRα) did not interest me given that the target was plagued by a history of failures. I was also aware of ImmunoGen’s mirvetuximab flunking a prior pivotal study and giving it a second try via registrational study in just the FRα high population. However, Sutro’s clinical readout for STRO-002 attracted my interest given impressive response rate and durability in a very heavily pretreated population (lends credence to management commentary that the drug is best-in-class as they did not have to stratify or enrich for FRα high expressors). On the con side, however, therapeutic window could be narrower than it originally appeared given the neutropenia events requiring dose reduction. Per my notes on Evercore presentation and KOL call, I came away with the impression that CEO Bill Newell was a straight shooter who clearly outlined benefits of the company’s cell free protein synthesis technology versus more traditional CHO or E coli cells (poor mechanism for discovery and scaling to commercial production). Cell free approach allowed the company to make many versions of a molecule rapidly, finding the best site of attachment and then varying linker & warhead to achieve optimal drug profile). Importantly, this approach allows them to rapidly scale and move forward (speed in the clinic). The purported advantages of this approach were apparent in STRO-002 data, (much greater tumor killing effect as drug doesn’t get removed when it’s internalized, has relatively fast clearance rate and half life of 2.5 hours versus 35 to 40 hours for the competition). They are able to get the molecule into the tumor microenvironment, do its job and minimize bystander effect to achieve a much better toxicity profile. Per initial phase 1 data update in all comers, 87% of adverse events were grade 1 or 2 (very manageable). Women in the study had 5 prior lines of therapy and life expectancy of 6 to 9 months (population you would NOT expect to see much activity in). Mid 20s response rate was quite promising in that light, not to mention duration of women on the study (including those with stable disease receiving clinical benefit for 12 weeks or longer). We compared these results to ImmunoGen’s mirvetuximab, which saw far fewer responses in dose escalation study and considerably less durability. Given 002’s initial data, I expected even better response/durability in earlier lines of therapy. One partnership that caught my attention was EMD Serono's EGFR-MUC1 bispecific ADC, which would be the first time in history that a bispecific, dual targeted ADC entered the clinic. The objective was to get away from the well-known toxicity profile of EGFR and preclinical data in NSCLC & esophageal squamous cell carcinoma showed complete tumor kill. Merck (MRK) collaboration in the area of cytokine derivatives continued to steadily move forward, with the big pharma company exercising option to extend research term. Lastly, I reminded readers that the company owned 1.6 million shares of Vaxcyte (PCVX) along with a 4% royalty. Corporate Slides Figure 2: Pipeline (Source: corporate presentation) As can be seen above, pipeline has expanded considerably since last time we revisited. Additionally, enterprise value of around $500 million has fallen considerably over the past year (to less than $100 million) despite clinical progress achieved. Select Recent Developments In May of 2021 the company shared additional dose escalation data for STRO-002 in patients with advanced ovarian cancer. Again, keep in mind these were heavily pretreated (6 prior lines of therapy). Of 31 patients, there was 1 complete response and four confirmed partial responses (5 unconfirmed PRs as well). Median progression free survival was 7.2 months, and again 86% of treatment emergent adverse events were Grade 1 or 2. Most common Grade 3 and 4 AEs were neutropenia, arthralgia, fatigue, neuropathy and abdominal pain (all manageable with treatment, dose reductions or dose delays). Dose limiting toxicities were observed at higher dose levels (6 mg/kg and 6.4 mg/kg) in two patients. Corporate Slides Figure 3: STRO-002 treatment shows promising signs of durability in dose escalation trial (Source: corporate presentation) Corporate Slides Figure 4: Anti-tumor activity observed across various FolRa-expression levels, suggestive of STRO-002 addressing a broader opportunity than its competition in FRa (Source: corporate presentation) In August the company appointed Jane Chung as Chief Commercial Officer (served prior as President of AstraZeneca, Canada). Later on in September, leadership team was expanded as well, with Nicole Chieffo joining as VP of Clinical Operations (formerly Sr Director, Oncology Global Operations Head at Janssen) and Werner Rubas joining as VP of Preclinical Operations (served prior at Nektar Therapeutics). On September 30th, it could be considered a green flag that Merck decided to extend research term for the first cytokine derivative program under 2018 collaboration agreement with Sutro. The two companies are pursuing a second candidate as well (uses different approach for the same target). Flash forward to December, where it appears that nonclinical data shows STRO-001 might not be as dead in the water as I thought it was (showed potential for CD74 in adult and pediatric AML and ALL). Additionally, STRO-002 was shown to have therapeutic potential in a rare, pediatric AML subtype expressing RolRa (CBFA2T3-GLIS2 fusion AML), in which preclinical model showed complete leukemia clearance. Of more material impact, December’s China licensing deal for STRO-002 with Tasly Biopharmaceuticals had interesting terms, including an impressive $40 million upfront cash payment (up to $345 million in milestone payments along with tiered, double-digit royalties). As noted prior, I found it highly interesting that language in the press release highlights potential to expand into additional oncology indications of NSCLC and TNBC (both of which represent sizeable opportunities that other FRα-targeting peers have not made inroads on). On January 5th the company reported interim data on its dose expansion study of STRO-002. ORR was 33% in 33 RECIST evaluable patients across all FolRa expression levels and both dose levels. However, ORR was 47% in 17 patients who started at the 5.2mg/kg dose level (keeping in mind some could not tolerate it and were stepped down to 4.3mg/kg). Interestingly enough, ORR of 40% was observed for patients with TPS score greater than 25%, which represents about 70% of the advanced ovarian cancer patient population (quite broad). Corporate Slides Figure 5: Change in sum diameters for target lesions over time (Source: corporate presentation) While the company touted "no new safety signals", it's still worth mentioning that the AE of note was neutropenia leading to treatment delay or dose reduction. However, the majority of these cases were asymptomatic and resolved with 1 week dose delay or standard medical treatment including use of G-CSF. It is a cause for concern that there were multiple cases of febrile neutropenia (one Grade 5 at 5.2 mg/kg, one Grade 3 at 4.3 mg/kg). Corporate Slides Figure 6: Emerging safety profile for STRO-002 (Source: corporate presentation) Moving on to June 27th, Sutro announced global collaboration with Astellas Pharma focused on development of novel immunostimulatory ADCs. The simple goal here is to bring new therapies to patients who do not respond to existing immunotherapies. iADCs will combine an antibody with a small molecule compound that induces immunogenic cell death in addition to an immune activating molecule, which in turn has the potential to boost anti-cancer action. Development will be pursued for 3 distinct biological targets, with each partner bringing unique expertise to the table (Sutro's being advanced technologies for drug linkers to antibodies and linkable cytotoxins). Importantly, Sutro is receiving $90M upfront and remains eligible to receive up to $422.5M in milestones for EACH product candidate along with tiered royalties ranging from low double-digit to mid-teens on worldwide sales. Management wisely retained the option to share in costs and profits for developing candidates in the US (commonly known as "co-development" option). This should not be overlooked, as commonly I see these smaller partners retain such options for perhaps one candidate involved in a particular deal but rarely as in this case for all of them. Lastly, on July 26th the company announced first patient had been dosed in phase 1 study of investigational candidate (novel cytokine derivative therapeutic) resulting from the collaboration between Sutro and Merck. Sutro received a $10M milestone payment and more importantly this represents important thesis progression as this partnership originated in July 2018 and is seeing its first drug candidate move forward in the clinic. Other Information For the second quarter of 2022, the company reported cash and equivalents of $191.6M (does not include $90M upfront payment from Astellas) as compared to operating expenses of $47.5M. I assume annual cash burn of $200M, which puts the company at just 1.5 years operational runway with current resources. At JMP presentation in June, CEO makes the following points: 6 clinical programs in development today, two of which are proprietary. They expect to integrate CDMOs into manufacturing as the company makes its way into late-stage studies. History of ADC field has been one of peaks and valleys. In past 5 years they've gained more understanding on how to optimize ADCs and get the desired targeted tumor kill with manageable safety profile. Goal is to attain superior efficacy and safety to chemotherapy, which is typically the alternative standard of care. Some ADCs are based on older technology, but chemistry and linkers used in Gen1 molecules are not state-of-the-art (heterogeneous mixtures). Competitors, including in ovarian cancer, use an average drug-antibody ratio because some species in vial are competent to do what they are supposed to do and others are not competent (i.e. some molecules with DAR of 4, some with 2 and not potent enough to get cell kill). Sutro believes that average is perhaps good enough in some circumstances, but far from optimal. Company believes homogeneity will allow them to have broader therapeutic window than competition along with better cell kill (optimized to do the job they want it to do, designing a better molecule and proving it in the clinic). For STRO-002 dose expansion phase, they are exploring two doses (5.2mg/kg and 4.3mg/kg). They are within therapeutic window of molecule with potential differences between efficacy and safety. Final data will be reported before year end. They hope to establish in platinum-resistant ovarian cancer population with up to 3 prior lines of therapy, that they can get robust response rates with good durability and meaningful progression-free survival for patients who do not respond. TMPS score above 25% is the ideal cutoff they've identified where patients have greater likelihood of responding to therapy (40% ORR versus low double digit response rate below this score). This break point gives them about 70% of market opportunity, perhaps as much as 80%. One competitor (ImmunoGen) identified a narrow therapeutic window for their molecule (6 mg/kg dosing regimen, as 7 mg/kg was too toxic and below 6 lacked efficacy). They also determined that they needed to use IHC assay and stick with only high expressors (smaller market opportunity). ImmunoGen reckons that allows for around 30% of the total market. Corporate Slides Figure 7: ImmunoGen estimated market opportunity in FRa-high patients (Source: corporate presentation) For STRO-002, they've already had FDA meeting regarding inclusion/exclusion criteria, patient selection, dosing strategy, path forward & pivotal trial design, etc. Conclusion is that they have the opportunity to do a registration-directed study with potential accelerated approval pathway depending on the quality of the data. That study will likely start in early 2023. As for bevacizumab combo study ongoing, bevacizumab is used much earlier in therapy (not reserved for late line). Almost 2/3rds of ovarian cancer patients are treated with bevacizumab in initial lines of therapy. They don't believe 1+1=5, in other words toxicity effects are not additive between the two agents. They started combo study at lower dose to ensure tolerability was there, then escalate up. Data will likely come in 2023. Analyst makes an important question for STRO-001 (go/no-go decision), given that multiple myeloma and NHL treatment landscape is shifting and increasingly crowded. They've seen promising early data including 1 CR and 2 PRs in 7 DLBCL patients along with decent safety profile (no ocular toxicity in either agent). 001 looks quite safe, they are still seeking efficacy signals at higher doses and it's been hard to recruit more patients recently (now enrolling ex-US where patients have less access to other treatments and have had fewer cycles of therapy). BioNova deal for 001 covers rest of costs to get to recommended phase 2 dose (using other people's money instead of burning company resources up). As for other partnered efforts, Bristol's (BMY) BCMA ADC continues to be optimized but CEO otherwise is not informed on how or if they will proceed forward. EMD Serono has initiated development of their MUC1-EGFR ADC and data is expected next year. Partner Merck is on the cusp as well with cytokine ADC. They've received almost $500M from partnerships and each one is about to have a product in the clinic. At end of Q1 they have $192M in bank, run rate takes them into 2H 2023. Final STRO-002 data analysis from expansion study will be single most important value driver, per Newell. Moving onto the virtual deep dive into iADC efforts, here were the key takeaways for me: ROR1 ADC is pursuing a target widely expressed a broad range of tumor types. STRO-003 (ROR1) will be their 7th product candidate to enter the clinic. ROR1 is an attract target due to its role in cancer progression and its specificity of expression on tumors (restricted on normal tissue so low potential for on-target toxicity). ROR1 is broadly expressed across heme malignancies as well as solid tumors including NSCLC and breast cancer. Prostate cancer for example has 90% and above prevalence (15% high grade, the lower that number is the more potent and efficient the ADC has to be). Other targets are active in preclinical pipeline, including Liv-1, PTK7, CEACAM5, Tissue Factor, etc. These are antigens management is very interested in at the moment (looking at them as both monospecific or potentially bispecific to combine with one another). As for Q&A, management states they've had a lot of interest from potential partners for their technology (not just Astellas). They are "open for business" and look forward to continuing discussions (sounds like more deal flow in the works). In regard to competitive data for ROR1 on the horizon, the company is still waiting to see how VelosBio data turns out in coming year or two. Readers may recall that VelosBio was acquired by Merck for $2.75 billion price tag for its ROR1 ADC in late 2020. At the time, data was scant but promising nonetheless (7/15 mantle cell lymphoma patients with complete responses, 4 of 5 patients in DLBCL cohort with complete responses). Merck had plans to move into triple negative breast cancer and non-small cell lung cancer, at the time. Sutro believes their epitope overlaps if not being identical to the VelosBio antibody (sounds like lack of differentiation here). They will be following the VelosBio program closely and this appears to be a "fast follower" situation where there's room for more than one winner. Corporate Slides Figure 8: ROR1 broadly expressed across wide range of tumor types (Source: corporate presentation) As for accumulated deficit, $334M as of December 31 seems quite reasonable for a company founded back in 2003 (well managed balance sheet and partnerships chipping in to offset cash burn). As for prior financings, December 2020 offering took place at $21 per share (3x upside from current levels). As for competition particularly in the FRa space, I'd like to point to data from MORAb-202, which was the subject of $3.1 billion joint development deal between Eisai (ESALF) (ESALY) and Bristol Myers ($650M upfront, up to $2.45 billion in milestones). MORAb-202 produced an impressive 52% ORR in higher dose cohort of Japanese PROC (platinum resistant ovarian cancer) patients. Importantly, here efficacy was seen IRRESPECTIVE of FRa levels. Median PFS was an impressive 8.2 months (I believe the bar was set at around 4 to 5 months by ImmunoGen). On the con side, the most common TEAE was interstitial lung disease (ILD)/pneumonitis at both dose levels (Cohort 1: 37.5% [n=9; 8 with grade 1, 1 with grade 2]; Cohort 2: 66.7% [n=14; 6 with grade 1, 7 with grade 2, 1 with grade 3]), which is a rough adverse event for patients to have to deal with. Responses were also observed in breast, endometrial and non-small cell lung cancer (phase 1/2 studies are now pursuing these indications).

Biotechs earnings growth	23.4%
Revenue growth rate	-22.2%
Future return on equity	n/a
Analyst coverage	Good
Last updated	01 May 2026

Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2028	22	-158	-152	-71	8
12/31/2027	24	-140	-123	-53	12
12/31/2026	32	-144	-128	-122	13
12/31/2025	102	-191	-179	-177	N/A
9/30/2025	106	-217	-225	-223	N/A
6/30/2025	104	-209	-252	-249	N/A
3/31/2025	66	-245	-199	-195	N/A
12/31/2024	62	-227	-195	-192	N/A
9/30/2024	161	-124	-109	-106	N/A
6/30/2024	169	-124	-78	-75	N/A
3/31/2024	154	-115	-119	-115	N/A
12/31/2023	154	-107	-116	-112	N/A
9/30/2023	49	-172	-156	-150	N/A
6/30/2023	57	-143	-57	-50	N/A
3/31/2023	75	-130	-29	-22	N/A
12/31/2022	68	-119	-4	4	N/A
9/30/2022	70	-123	-1	6	N/A
6/30/2022	53	-134	-96	-84	N/A
3/31/2022	53	-114	-101	-87	N/A
12/31/2021	62	-106	-97	-82	N/A
9/30/2021	60	-127	-93	-79	N/A
6/30/2021	69	-79	-85	-72	N/A
3/31/2021	50	-43	-88	-79	N/A
12/31/2020	43	-32	-75	-68	N/A
9/30/2020	46	13	-70	-62	N/A
6/30/2020	40	-17	-66	-61	N/A
3/31/2020	41	-61	-68	-64	N/A
12/31/2019	43	-56	-69	-65	N/A
9/30/2019	51	-42	N/A	-58	N/A
6/30/2019	46	-40	N/A	6	N/A
3/31/2019	41	-38	N/A	8	N/A
12/31/2018	38	-35	N/A	13	N/A
9/30/2018	23	-49	N/A	14	N/A
6/30/2018	33	-40	N/A	-36	N/A
3/31/2018	42	-30	N/A	-37	N/A
12/31/2017	52	-20	N/A	-37	N/A
12/31/2016	60	N/A	N/A	-13	N/A

Data	Last Updated (UTC time)
Company Analysis	2026/05/07 14:44
End of Day Share Price	2026/05/07 00:00
Earnings	2025/12/31
Annual Earnings	2025/12/31

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

Analyst	Institution
Zhiqiang Shu	Berenberg
Tazeen Ahmad	BofA Global Research
Thomas Shrader	BTIG

Sutro Biopharma Future Growth

Future criteria checks 0/6

Key information

Recent future growth updates

Analysts Are Upgrading Sutro Biopharma, Inc. (NASDAQ:STRO) After Its Latest Results

Consensus revenue estimates fall by 16%

Price target decreased by 7.1% to US$12.80

Price target decreased by 12% to US$12.89

Consensus revenue estimates fall by 28%

Price target decreased by 13% to US$14.67

Recent updates

Sutro Biopharma: Recycling Past Data Ahead Of The Readout, Sell

STRO: ADC Progress And Equity Offering Will Shape Balanced Future Outlook

Sutro Biopharma, Inc., Annual General Meeting, Jun 05, 2026

Sutro Biopharma Presents Promising Preclinical Data Across Its Pipeline of Next-Generation Single and Dual-Payload Adc Programs

STRO: Equity Offering And Lockup Structure Will Support Future Upside

STRO: Recent Equity Raises And Lockup Structure Will Support Future Upside

Sutro Biopharma, Inc. has filed a Follow-on Equity Offering in the amount of $100 million.

STRO: Equity Raise And Index Removal Will Set Up Future Upside Potential

STRO: Reverse Split And Equity Raise Will Support Future Upside

Sutro Biopharma, Inc. has completed a Follow-on Equity Offering in the amount of $109.999994 million.

STRO: Reverse Split And ADC Pipeline Progress Will Support Future Upside Potential

Here's Why We're A Bit Worried About Sutro Biopharma's (NASDAQ:STRO) Cash Burn Situation

STRO: Reverse Split And ADC Pipeline Progress Will Drive Future Upside

STRO: Reverse Split And ADC Pipeline Progress Will Support Future Upside

Sutro Biopharma, Inc.'s (NASDAQ:STRO) Price Is Right But Growth Is Lacking After Shares Rocket 46%

STRO: Reverse Split And ADC Pipeline Focus Will Drive Future Upside

Sutro Biopharma, Inc. Announces First Cohort of Patients Dosed in Phase 1 Trial of STRO-004, a Next-Generation Tissue Factor ADC, in Tissue Factor

STRO: Reverse Split And ADC Focus Will Drive Long-Term Upside

Sutro Biopharma, Inc. Highlights Next-Generation ADC Innovation at Virtual R&D Day

Sutro Biopharma Announces Operational Restructuring Intended to Extend Cash Runway Through Key Milestones

ADC Pipeline Focus Will Advance Preclinical Drug Development

Here's Why We're A Bit Worried About Sutro Biopharma's (NASDAQ:STRO) Cash Burn Situation

Sutro Biopharma, Inc.(NasdaqGM:STRO) dropped from Russell 2000 Dynamic Index

Sutro Biopharma Receives Written Notice from the Nasdaq Stock Market

Sutro Biopharma, Inc Appoints Greg Chow as Chief Financial Officer, Effective June 2, 2025

Benign Growth For Sutro Biopharma, Inc. (NASDAQ:STRO) Underpins Stock's 36% Plummet

Sutro Biopharma, Inc., Annual General Meeting, Jun 06, 2025

John Freund Decides Not to Stand for Re-Election At the AGM of Sutro Biopharma, Inc

ADC Pipeline Focus Will Advance Preclinical Drug Development

Sutro Biopharma, Inc. Presents Data from Dose-Optimization Portion of Reframe-O1 Trial in Patients with Platinum Resistant Ovarian Cancer At SGO 2025

Sutro Biopharma Announces CEO Changes

Sutro Biopharma, Inc. (NASDAQ:STRO) Not Doing Enough For Some Investors As Its Shares Slump 25%

Sutro Biopharma: I Don't Buy That Their Pipeline Is Worthless

Sutro Biopharma Announces Selected Dose for Luvelta and Topline Results from Dose-Optimization Portion of Reframe-O1 Trial in Platinum Resistant Ovarian Cancer

Why Investors Shouldn't Be Surprised By Sutro Biopharma, Inc.'s (NASDAQ:STRO) 26% Share Price Plunge

Sutro Biopharma, Inc. Announces Initiation of the Registration-Enabling REFRaME-P1 Trial with Luvelta for Pediatric Patients with CBF/GLIS AML

Revenues Working Against Sutro Biopharma, Inc.'s (NASDAQ:STRO) Share Price Following 25% Dive

Sutro Biopharma Highlights Next-Generation ADC Innovation and Near-Term Pipeline At Research Forum

Sutro Biopharma's Competitive ADCs Position It For Future Growth In Oncology

Sutro Biopharma Announces Updated Data from Phase 1b Study of Luvelta in Combination with Bevacizumab at ESMO2024

There's No Escaping Sutro Biopharma, Inc.'s (NASDAQ:STRO) Muted Revenues Despite A 29% Share Price Rise

Brokers Are Upgrading Their Views On Sutro Biopharma, Inc. (NASDAQ:STRO) With These New Forecasts

Sutro Biopharma Announces Initiation of REFRaME-L1 Phase 2 Trial with Luvelta for Patients with Non-Small Cell Lung Cancer

Analysts Are Upgrading Sutro Biopharma, Inc. (NASDAQ:STRO) After Its Latest Results

Sutro Biopharma Appoints Dr. Barbara Leyman as Chief Business Development Officer

The Market Doesn't Like What It Sees From Sutro Biopharma, Inc.'s (NASDAQ:STRO) Revenues Yet As Shares Tumble 28%

We Think The Compensation For Sutro Biopharma, Inc.'s (NASDAQ:STRO) CEO Looks About Right

Consensus revenue estimates fall by 16%

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target decreased by 7.1% to US$12.80

Sutro Biopharma, Inc. Announces Initiation of Randomized Portion (Part 2) of REFRaME-O1 Trial

Sutro Biopharma, Inc., Annual General Meeting, Jun 06, 2024

Price target decreased by 12% to US$12.89

Sutro Biopharma, Inc. has completed a Follow-on Equity Offering in the amount of $74.999998 million.

Bearish: Analysts Just Cut Their Sutro Biopharma, Inc. (NASDAQ:STRO) Revenue and EPS estimates

Sutro Biopharma, Inc. has filed a Follow-on Equity Offering in the amount of $74.999998 million.

Consensus revenue estimates fall by 28%

The Market Doesn't Like What It Sees From Sutro Biopharma, Inc.'s (NASDAQ:STRO) Revenues Yet

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Chief Medical Officer exercised options and sold US$64k worth of stock

Insider notifies of intention to sell stock

Sutro Biopharma Highlights Potential Multi-Cancer Opportunity for Luvelta, a FolRa-Targeting ADC

Sutro Biopharma, Inc.'s (NASDAQ:STRO) Price Is Right But Growth Is Lacking After Shares Rocket 43%

Price target decreased by 13% to US$14.67

Sutro Biopharma, Inc. Announces New Positive Data from the Compassionate Use of Luveltamab Tazevibulin (luvelta) in Pediatric Patients with Relapsed/Refractory CBF/GLIS Presented at ASH 2023

Sutro Biopharma, Inc Appoints Jane Chung as President and Chief Operating Officer

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

New minor risk - Share price stability

Sutro Biopharma Announces Presentation of Data for Luveltamab Tazevibulin (luvelta) from the Phase 1 Dose-Expansion Study in Endometrial Cancers At ESMO 2023